Antifungal activity of C18 peptide

The novel synthesized Ceropin-4 derived peptide, C18(LWKIGKKIWRVLWNWR), showed high activity against C. albicans, with reference in our previous study (Peng et al., 2021 (link)). Consequently, C18 was synthesized by Gil Biochemical Co., Ltd. (Shanghai, China) with purity >95%, as verified by high-performance liquid chromatography (HPLC) and mass spectrometry. Fluconazole (FLZ) was purchased from Sigma-Aldrich. Other reagents were obtained from solarbio (Beijing, China) unless indicated otherwise.

Free full text: Click here

Sun C.Q., Peng J., Yang L.B., Jiao Z.L., Zhou L.X., Tao R.Y., Zhu L.J., Tian Z.Q., Huang M.J, & Guo G. (2022). A Cecropin-4 Derived Peptide C18 Inhibits Candida albicans by Disturbing Mitochondrial Function. Frontiers in Microbiology, 13, 872322.

Publication 2022

Fluconazole (FLZ)

Fluconazole High performance liquid chromatography Mass spectrometry Peptide

Corresponding Organization : Guiyang Medical University

Other organizations : Affiliated Hospital of Guizhou Medical University

Top 5 similar protocols

Variable analysis

independent variables

Ceropin-4 derived peptide C18

dependent variables

Activity against C. albicans

control variables

Fluconazole (FLZ)

controls

Positive control: Fluconazole (FLZ)

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!